The phase 2 trial involved 560 healthy volunteers, and results show that the vaccine was able to prompt a response to COVID-19 within 14 days of the first dose. It produces a similar immune response among adults of all ages.
People over the age of 70 are at a high risk of developing severe illness if they contract COVID-19. The vaccine is now in phase 3 trials and is being tested to see if it can protect the elderly and people with underlying health conditions from COVID-19, The Hill reported.
Phase 3 trial results should be known by Christmas, AstraZeneca and the University of Oxford said.
Find the full study results here.
More articles on pharmacy:
3 key vaccine production challenges drugmakers are facing
What Amazon’s online pharmacy announcement did to CVS, Walgreens and Rite Aid stock
Every state will have COVID-19 vaccine within 24 hours of FDA’s OK, federal officials say
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
